{"id":"placebo-azathioprine","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Bone marrow suppression / leukopenia"},{"rate":"10-12","effect":"Nausea and vomiting"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Infection"},{"rate":"1-2","effect":"Pancreatitis"},{"rate":"1-3","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azathioprine acts as an immunosuppressant by interfering with nucleotide metabolism, particularly purine synthesis. After hepatic conversion to 6-mercaptopurine and further metabolism, it inhibits the proliferation of lymphocytes, reducing both cellular and humoral immune responses. This makes it effective in preventing organ rejection and treating autoimmune conditions.","oneSentence":"Azathioprine is a prodrug that is converted to 6-mercaptopurine, which inhibits purine synthesis and suppresses T-cell and B-cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:37.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients"},{"name":"Autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":"Ulcerative Colitis","enrollment":355},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT03164473","phase":"PHASE3","title":"Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-07","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":98},{"nctId":"NCT05030155","phase":"PHASE3","title":"Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-30","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT00647166","phase":"PHASE3","title":"Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-05","conditions":"MPA, PAN or EGPA With FFS=0, At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids","enrollment":114},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":"Dermatomyositis","enrollment":62},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT06925698","phase":"PHASE3","title":"Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","status":"NOT_YET_RECRUITING","sponsor":"Marmara University","startDate":"2025-04-30","conditions":"Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses","enrollment":110},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT06226662","phase":"PHASE2","title":"Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":12},{"nctId":"NCT05349006","phase":"PHASE3","title":"Azathioprine in MOGAD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-12-12","conditions":"Central Nervous System Inflammation, MOG-IgG Associated Disease","enrollment":126},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":3},{"nctId":"NCT04654988","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2022-12-01","conditions":"Myocarditis, Heart Failure, Endomyocardial Biopsy","enrollment":100},{"nctId":"NCT04713631","phase":"PHASE2","title":"Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease","status":"UNKNOWN","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2021-01-21","conditions":"Crohn's Disease","enrollment":40},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT02028884","phase":"PHASE3","title":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-20","conditions":"Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)","enrollment":85},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT00539838","phase":"PHASE3","title":"A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-12-19","conditions":"Systemic Lupus Erythematosus","enrollment":33},{"nctId":"NCT04371718","phase":"PHASE2","title":"Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)","status":"UNKNOWN","sponsor":"TaiwanJ Pharmaceuticals Co., Ltd","startDate":"2020-11","conditions":"Autoimmune Hepatitis","enrollment":120},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT02789397","phase":"PHASE2","title":"Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-05-02","conditions":"Granulomatous and Lymphocytic Interstitial Lung Disease","enrollment":""},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT02579733","phase":"PHASE4","title":"Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis","status":"TERMINATED","sponsor":"Kyungpook National University Hospital","startDate":"2016-02-01","conditions":"Ulcerative Colitis","enrollment":16},{"nctId":"NCT03498703","phase":"PHASE2","title":"Azathioprine in Recurrent Implantation Failure","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-04-25","conditions":"Recurrent Implantation Failure, In Vitro Fertilization, Intracytoplsmic Sperm Injection","enrollment":64},{"nctId":"NCT01663623","phase":"PHASE3","title":"Belimumab in Remission of VASculitis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2013-03-20","conditions":"Vasculitis","enrollment":106},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT00104299","phase":"PHASE2, PHASE3","title":"Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":197},{"nctId":"NCT00537316","phase":"PHASE3","title":"Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Ulcerative Colitis","enrollment":242},{"nctId":"NCT00796250","phase":"PHASE3","title":"Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-11-01","conditions":"Crohn's Disease","enrollment":9},{"nctId":"NCT00094458","phase":"PHASE3","title":"Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC","status":"COMPLETED","sponsor":"Centocor Ortho Biotech Services, L.L.C.","startDate":"2005-03","conditions":"Crohn Disease","enrollment":508},{"nctId":"NCT00774852","phase":"PHASE2","title":"Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Lupus Nephritis, Lupus Erythematosus, Systemic","enrollment":137},{"nctId":"NCT02496182","phase":"PHASE2, PHASE3","title":"Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment","status":"UNKNOWN","sponsor":"Grupo Medifarma, S. A. de C. V.","startDate":"2015-07","conditions":"Alveolitis Extrinsic Allergic, Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT00650091","phase":"PHASE3","title":"Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-10","conditions":"Pulmonary Fibrosis","enrollment":264},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT01817972","phase":"PHASE3","title":"Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease","status":"UNKNOWN","sponsor":"Gastroenterology Research of America","startDate":"2013-03","conditions":"Crohn's Disease","enrollment":65},{"nctId":"NCT00447265","phase":"PHASE2","title":"Etanercept for the Treatment of Lupus Nephritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-02","conditions":"Lupus Nephritis","enrollment":1},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00946946","phase":"PHASE3","title":"Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2002-02","conditions":"Crohn's Disease","enrollment":78},{"nctId":"NCT00377637","phase":"PHASE3","title":"A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Lupus Nephritis","enrollment":370},{"nctId":"NCT00626678","phase":"PHASE2","title":"Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2008-01","conditions":"Pemphigus Vulgaris","enrollment":48},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00997412","phase":"NA","title":"Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis","status":"UNKNOWN","sponsor":"Qualitix Clinical Research Co., Ltd.","startDate":"2009-05","conditions":"Myasthenia Gravis","enrollment":40},{"nctId":"NCT00368264","phase":"PHASE2, PHASE3","title":"TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2006-09","conditions":"Lupus Erythematosus, Systemic, Lupus Nephritis","enrollment":1},{"nctId":"NCT00518310","phase":"NA","title":"Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Thorax National Institute","startDate":"2005-05","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo Azathioprine","genericName":"Placebo Azathioprine","companyName":"Medical University of Warsaw","companyId":"medical-university-of-warsaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azathioprine is a prodrug that is converted to 6-mercaptopurine, which inhibits purine synthesis and suppresses T-cell and B-cell proliferation. Used for Prevention of organ rejection in transplant recipients, Autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}